ArticleJournal of the American Heart Association2026
Fibroblast-Derived Microfibrillar-Associated Protein 5 Exerts Cardioprotective Effects After Myocardial Infarction by Activating the NOTCH2 Signaling in Cardiomyocytes.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. MFAP5 (microfibrillar-associated protein 5) is an extracellular-matrix associated secreted glycoprotein whose cardiac function is unknown. This study aimed to explore the origin, expression, function, and potential mechanisms of MFAP5 in MI.
methodsSingle-cell analysis and immunohistochemistry were used to determine the origin and expression of MFAP5. Global MFAP5-knockout (KO) mice and adeno-associated virus 9-mediated cardiac fibroblast-specific overexpression mice were used to investigate the function of MFAP5 in vivo. RNA sequencing and ingenuity pathway analysis revealed potential mechanisms. Coimmunoprecipitation and confocal microscopy identified molecular interaction domains. rMFAP5 (recombinant MFAP5 protein) and plasmid-mediated intracellular overexpression revealed the effects of MFAP5 on cardiomyocytes under oxygen-glucose deprivation conditions.
resultsMFAP5 was significantly increased in both human and mouse heart tissues during MI, predominantly derived from activated cardiac fibroblasts. In vivo, MFAP5-knockout exacerbated cardiac dysfunction, enlarged infarct size and increased cardiomyocyte apoptosis during the acute phase of MI. Cardiac fibroblast-specific overexpression of MFAP5 exerted a protective effect. In vitro, MFAP5 significantly inhibited apoptosis in cardiomyocytes under oxygen-glucose deprivation stimulation. Mechanistically, MFAP5 derived from fibroblasts interacted with the extracellular EGF (epidermal growth factor) repeats of the NOTCH2 receptor on the surface of cardiomyocytes via its MBD domain, promoting shedding of the extracellular fragment of NOTCH2 and generation of the NICD2 (NOTCH2 intracellular domain). MFAP5 inhibited cardiomyocyte apoptosis by activating NOTCH2 signaling.
conclusionsFibroblast-derived MFAP5 engages cardiomyocyte NOTCH2 to inhibit apoptosis and exerts cardioprotective effects after MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.